Suzetrigine for Opioid-Free Recovery After Cesarean Delivery

This is a single-site, randomized, double-blind, placebo-controlled clinical trial evaluating whether adjunctive suzetrigine increases the proportion of patients who remain opioid-free following cesarean delivery. The study is conducted at a tertiary care academic medical center.

Participants undergoing cesarean delivery under neuraxial anesthesia are randomized in a 1:1 ratio to receive either oral suzetrigine or a matching placebo following surgery. Randomization is performed using a computer-generated sequence with permuted blocks of variable size and allocation concealment through a secure electronic system. Participants, clinicians, investigators, and study personnel are blinded to treatment assignment.

The intervention consists of oral suzetrigine administered in the immediate postoperative period, beginning with a loading dose within 90 minutes after skin closure, followed by scheduled maintenance dosing every 12 hours. Participants randomized to the control arm receive a matching placebo on the same schedule. Study medication is prepared and dispensed by the investigational pharmacy in identical packaging to maintain blinding.

All participants receive standardized multimodal postoperative analgesia consistent with institutional enhanced recovery pathways, including scheduled acetaminophen and non-steroidal anti-inflammatory drugs, as well as neuraxial morphine administered intraoperatively. Opioid medications remain available for breakthrough pain at the discretion of the clinical care team.

Suzetrigine is a selective NaV1.8 voltage-gated sodium channel inhibitor that targets peripheral nociceptive pathways and does not act on opioid receptors. This study evaluates its use as an adjunct to standard multimodal analgesia in a postpartum surgical population in which opioid exposure remains common despite guideline-recommended care.

Participants are followed during their inpatient hospitalization and through the early postpartum period using a combination of electronic medical record data and structured follow-up assessments to capture medication use, recovery, and patient-reported outcomes. Data are recorded using secure electronic data capture systems with predefined data fields and standardized collection procedures.

Analyses will be conducted using an intention-to-treat approach, with comparisons between randomized groups based on pre-specified analytical methods appropriate for outcome type.

Participant safety is monitored throughout the study period through routine clinical care, structured follow-up assessments, and oversight by an independent data safety monitoring board.

Inclusion criteria

• Women aged ≥18 years.
• Undergoing scheduled or unscheduled cesarean delivery during the current admission, with or without concomitant salpingectomy.
• Planned delivery under neuraxial anesthesia (spinal, epidural, or combined spinal-epidural).
• Planned Pfannenstiel skin incision.
• Able to provide informed consent in English or Spanish.
• Willing and able to complete required remote follow-up assessments through postoperative day 14 (POD14).

Exclusion criteria

• Planned provision of breast milk to the neonate during the period of suzetrigine exposure (while the study drug is being taken and for 96 hours after last dose), due to the absence of human lactation safety data for suzetrigine.*
• Known allergy, hypersensitivity, or contraindication to suzetrigine or any component of its formulation.
• Chronic opioid use, defined as daily opioid use for more than 7 consecutive days in the month prior to delivery, or current treatment for opioid use disorder.
• Significant hepatic disease, defined as AST or ALT >3 times the upper limit of normal or Child-Pugh class B or C.
• Severe renal impairment, defined as estimated glomerular filtration rate (eGFR) <15 mL/min.
• Concurrent use of medications known to significantly alter suzetrigine metabolism, including strong CYP3A inhibitors or inducers, such as:

• ketoconazole
• ritonavir
• carbamazepine
• rifampin
• St. John's wort (or other agents deemed clinically significant CYP3A modulators by the study investigator team)
• Planned cesarean delivery under general anesthesia without neuraxial anesthesia.
• Planned non-Pfannenstiel skin incision (e.g., vertical midline incision).
• Participation in another interventional pain-management clinical trial during the current hospitalization.
• Additional operative procedures (excluding salpingectomy) performed at the time of cesarean delivery (e.g., hysterectomy, hernia repair).
• Inability to provide informed consent or to complete required study procedures and follow-up.
• Receipt of opioid or sedating medications prior to completion of the informed consent process.

• Feeding decisions are made independently of study participation. The study does not require participants to alter infant feeding plans; eligibility is determined solely by whether breast milk will be provided to the neonate during the period of study drug exposure (while the study drug is being taken and for 96 hours after last dose). Participants who plan to breastfeed but independently elect not to provide breast milk to the neonate during the period of suzetrigine exposure are eligible.